α-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis
Open Access
- 19 August 2010
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 162 (1), 178-187
- https://doi.org/10.1111/j.1365-2249.2010.04233.x
Abstract
Myocarditis is an inflammation of the myocardium which often follows virus infections. Coxsackievirus B3 (CVB3), as a marker of the enterovirus group, is one of the most important infectious agents of virus-induced myocarditis. Using a CVB3-induced myocarditis model, we show that injection α-galactosylceramide (α-GalCer), a ligand for invariant natural killer (NK) T (iNK T) cells, can protect the mice from viral myocarditis. After the systemic administration of α-GalCer in CVB3 infected mice, viral transcription and titres in mouse heart, sera and spleen were reduced, and the damage to the heart was ameliorated. This is accompanied by a better disease course with an improved weight loss profile. Compared with untreated mice, α-GalCer-treated mice showed high levels of interferon (IFN)-γ and interleukin (IL)-4, and reduced proinflammatory cytokines and chemokines in their cardiac tissue. Anti-viral immune response was up-regulated by α-GalCer. Three days after CVB3 infection, α-GalCer-administered mice had larger spleens. Besides NK T cells, more macrophages and CD8+ T cells were found in these spleens. Upon stimulation with phorbol myristate acetate plus ionomycin, splenocytes from α-GalCer-treated mice produced significantly more cytokines [including IFN-γ, tumour necrosis factor-α, IL-4 and IL-10] than those from untreated mice. These data suggest that administration of α-GalCer during acute CVB3 infection is able to protect the mice from lethal myocarditis by local changes in inflammatory cytokine patterns and enhancement of anti-viral immune response at the early stage. α-GalCer is a potential candidate for viral myocarditis treatment. Our work supports the use of anti-viral treatment early to reduce the incidence of virus-mediated heart damage.This publication has 35 references indexed in Scilit:
- Treatment of viral myocarditis caused by coxsackievirus BAmerican Journal of Health-System Pharmacy, 2008
- Invariant NKT cells sustain specific B cell responses and memoryProceedings of the National Academy of Sciences of the United States of America, 2007
- TheIn VivoResponse of Invariant Natural Killer T Cells to Glycolipid AntigensInternational Reviews of Immunology, 2007
- Corticosteroids for viral myocarditisPublished by Wiley ,2006
- Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis CGut, 2006
- Cooperative Regulation of the Host Defense to Cryptococcal Infection by Innate Immune LymphocytesNippon Ishinkin Gakkai Zasshi, 2006
- Therapeutic Potential of Glycolipid Ligands for Natural Killer (NK) T Cells in the Suppression of Autoimmune DiseasesCurrent Drug Target - Immune, Endocrine & Metabolic Disorders, 2005
- Glycolipid antigen induces long-term natural killer T cell anergy in miceJCI Insight, 2005
- NKT Cells Are Critical for the Initiation of an Inflammatory Bowel Response againstToxoplasma gondiiThe Journal of Immunology, 2005
- Role of natural killer T (NKT) cells lacking interleukin (IL)-4 producing abilities on the CC-chemokine ligand 2-associated herpes simplex virus type 1 infection in human severe combined immunodeficiency (SCID) mouse chimerasClinical Dermatology and Surgery, 2005